Public Profile

Zogenix, Inc.

Zogenix, Inc., a prominent biopharmaceutical company headquartered in the United States, focuses on developing and commercialising innovative therapies for patients with rare neurological diseases. Founded in 2013, Zogenix has made significant strides in the industry, particularly with its flagship product, Fintepla, which is designed to treat Dravet syndrome, a severe form of epilepsy. With a commitment to addressing unmet medical needs, Zogenix operates primarily in the US and has expanded its reach to international markets. The company is recognised for its unique approach to drug development, leveraging advanced formulations to enhance patient outcomes. Zogenix's dedication to innovation and patient care has solidified its position as a leader in the biopharmaceutical sector, earning accolades for its contributions to the treatment of complex neurological disorders.

DitchCarbon Score

How does Zogenix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Zogenix, Inc.'s score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Zogenix, Inc.'s reported carbon emissions

Zogenix, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As a result, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the absence of specific data, it is unclear how Zogenix is addressing climate change or contributing to sustainability efforts within the pharmaceutical industry.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Zogenix, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Zogenix, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Zogenix, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

INJEX Pharma AG

DE
Other land transportation services
Updated about 22 hours ago

Collegium Pharmaceutical, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated about 22 hours ago

Janssen

US
Pharmaceutical Preparation Manufacturing
Updated about 22 hours ago

Eternity Healthcare, Inc.

HK
Health and social work services (85)
Updated about 22 hours ago

Penjet Corporation

US
Updated about 22 hours ago

Becton Dickinson, S.A.

ES
Medical, precision and optical instruments, watches and clocks (33)
Updated 3 months ago
DitchCarbon Score

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers